Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J Link

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The Lancet. Infectious Diseases|June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response studyD Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
JAMA|March 6, 2015
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestickLilin Lai, Richard Davey, Allison Beck, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The Lancet. Infectious Diseases|June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response studyD Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
JAMA|March 6, 2015
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestickLilin Lai, Richard Davey, Allison Beck, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Pageof 3